Multimarker approach for the prediction of cardiovascular events in patients with mild to moderate coronary artery lesions a 3-year follow-up study

International Heart Journal

Volumn 53, Issue 2, 2012, Pages 85-90

  Zhang, Min ^a   Lu, Shuzheng ^a   Wu, Xiaofan ^a   Chen, Yundai ^b   Song, Xiantao ^a   Jin, Zening ^a   Li, Hong ^a   Zhou, Yujie ^a   Chen, Fang ^a   Huo, Yong ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Mild to moderate lesions; Multimarker score; Risk factors

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CATHEPSIN S; CD40 LIGAND; CXCL16 CHEMOKINE; CYSTATIN S; GELATINASE B; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACENTAL GROWTH FACTOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CATHEPSINS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREGNANCY PROTEINS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; RISK FACTORS; YOUNG ADULT;

EID: 84861317683     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.53.85     Document Type: Article

References (41)

1. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-26. (Review)
2. Shishehbor MH, Bhatt DL. Inflammation and atherosclerosis. Curr Atheroscler Rep 2004; 6: 131-9. (Review)
3. Libby P. Changing concepts of atherogenesis. J Intern Med 2000; 247: 349-58. (Review)
4. Ambrose JA, Winters SL, Arora RR, et al. Angiographic evolution of coronary artery morphology in unstable angina. J Am Coll Cardiol 1986; 7: 472-8.
5. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988; 78: 1157-66.
6. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988; 12: 56-62.
7. Stone GW, Maehara A, Lansky AJ, et al. A prospective naturalhistory study of coronary atherosclerosis. N Engl J Med 2011; 364: 226-35.
8. Fernandes MR, Silva GV, Caixeta A, Rati M, de Sousa e Silva NA, Perin EC. Assessing intermediate coronary lesions: angiographic prediction of lesion severity on intravascular ultrasound. J Invasive Cardiol 2007; 19: 412-6.
9. Zakynthinos E, Pappa N. Inflammatory biomarkers in coronary artery disease. J Cardiol 2009; 53: 317-33. (Review)
10. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
11. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290: 898-904.
12. Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003; 290: 891-7.
13. Magnus P, Beaglehole R. The real contribution of the major risk factors to the coronary epidemics: time to end the "only-50%" myth. Arch Intern Med 2001; 161: 2657-60.
14. Liu J, Ma L, Yang J, et al. Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis 2006; 186: 411-9.
15. Jansson AM, Aukrust P, Ueland T, et al. Soluble CXCL16 predicts long-term mortality in acute coronary syndromes. Circulation 2009; 119: 3181-8.
16. Lehrke M, Millington SC, Lefterova M, et al. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. J Am Coll Cardiol 2007; 49: 442-9.
17. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-11.
18. Yan JC, Zhu J, Gao L, et al. The effect of elevated serum soluble CD40 ligand on the prognostic value in patients with acute coronary syndromes. Clin Chim Acta 2004; 343: 155-9.
19. Heeschen C, Dimmeler S, Hamm CW, et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 2003; 107: 2109-14.
20. Heeschen C, Dimmeler S, Fichtlscherer S, et al. Prognostic value of placental growth factor in patients with acute chest pain. JAMA 2004; 291: 435-41.
21. Apple FS, Wu AH, Mair J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005; 51: 810-24. (Review)
22. Lenderink T, Heeschen C, Fichtlscherer S, et al. Elevated placental growth factor levels are associated with adverse outcomes at fouryear follow-up in patients with acute coronary syndromes. J Am Coll Cardiol 2006; 47: 307-11.
23. Brown DA, Breit SN, Buring J, et al. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet 2002; 359: 2159-63.
24. Lind L, Wallentin L, Kempf T, et al. Growth-differentiation factor- 15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J 2009; 30: 2346-53.
25. Eggers KM, Kempf T, Lagerqvist B, et al. Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome. Circ Cardiovasc Genet 2010; 3: 88-96.
26. Blankenberg S, Rupprecht HJ, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107: 1579-85.
27. de Lemos JA, Morrow DA, Sabatine MS, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003; 107: 690-5.
28. Koenig W, Löwel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004; 109: 1349-53.
29. Cushman M, Arnold AM, Psaty BM, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 2005; 112: 25-31.
30. Auer J, Berent R, Lassnig E, Eber B. C-reactive protein and coronary artery disease. Jpn Heart J 2002; 43: 607-19.
31. Zethelius B, Berglund L, SundstrÖm J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358: 2107-16.
32. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003; 108: 2317-22.
33. Ardigo D, Assimes TL, Fortmann SP, et al. Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease. Physiol Genomics 2007; 31: 402-9.
34. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631-9.
35. Braunwald E. Unstable angina. A classification. Circulation 1989; 80: 410-4.
36. Blankenberg S, McQueen MJ, Smieja M, et al. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2006; 114: 201-8.
37. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
38. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351: 2599-610.
39. Wilson PW, Nam BH, Pencina M, D'Agostino RB Sr, Benjamin EJ, O'Donnell CJ. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 2005; 165: 2473-8.
40. Miller M, Zhan M, Havas S. High attributable risk of elevated Creactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med 2005; 165: 2063-8.
41. Pijls NH, van Schaardenburgh P, Manoharan G, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol 2007; 49: 2105-11.